Business
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nShield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing Shield blood test directly to Americans\n\n\n\nRoute will focus on rural communities across the country with the lowest screening rates and highest CRC incidence and mortality\n\n\n\nShield is proven to increase screening rates with a 93% adherence\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and recommended in national guidelines, directly to over 100 communities across the country from Las Vegas to Hartford, Atlanta and more.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304217437/en/Mobile screening bus providing Shield by Guardant Health, the first and only FDA-approved blood test for primary colorectal cancer screening\nFrom national sporting events to rural senior centers and beyond, the tour will educate patients on the importance of CRC screening and provide patients of screening-eligible age the opportunity to screen with Shield via the mobile screening lab. The Shield Across America tour will focus on rural areas that face the biggest barriers to colorectal cancer screening and the highest incidence and mortality rates.\n\n\nThe tour launch coincides with National CRC Awareness Month, underscoring Guardant Health’s commitment to close America’s colorectal cancer screening gap and help more Americans get screened.\n\n\nCRC remains the second leading cause of cancer-related deaths in the U.S., and recently the leading cancer death for those under 50. Despite being highly treatable when caught early, more than 54 million eligible Americans – 1 in 3 – do not complete their CRC screening because they find current options unpleasant or inconvenient. Shield Across America aims to eliminate the barriers that have kept many Americans from getting screened by expanding access to Shield through mobile screening lab stops nationwide.\n\n\n“Shield Across America seeks to address a fundamental challenge in colorectal canc...